Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. [electronic resource]
Producer: 20110418Description: 543-8 p. digitalISSN:- 1555-8576
- Adult
- Aged
- Aged, 80 and over
- Anemia -- chemically induced
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Diphosphonates -- administration & dosage
- Docetaxel
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Feasibility Studies
- Fever -- chemically induced
- Humans
- Imidazoles -- administration & dosage
- Infusions, Intravenous
- Interleukin-8 -- blood
- Male
- Matrix Metalloproteinase 2 -- blood
- Matrix Metalloproteinase 9 -- blood
- Middle Aged
- Neutropenia -- chemically induced
- Orchiectomy
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Taxoids -- administration & dosage
- Treatment Outcome
- Zoledronic Acid
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.